Stocks and Investing
Stocks and Investing
Wed, April 26, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Andrew Fein Reiterated (BIIB) at Strong Buy and Held Target at $325 on, Apr 26th, 2023
Andrew Fein of HC Wainwright & Co., Reiterated "Biogen Inc." (BIIB) at Strong Buy and Held Target at $325 on, Apr 26th, 2023.
Andrew has made no other calls on BIIB in the last 4 months.
There are 6 other peers that have a rating on BIIB. Out of the 6 peers that are also analyzing BIIB, 1 agrees with Andrew's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Geoff Meacham of "B of A Securities" Maintained at Hold with Increased Target to $300 on, Friday, April 21st, 2023
These are the ratings of the 5 analyists that currently disagree with Andrew
- Jasper Hellweg of "Argus Research" Maintained at Strong Buy with Increased Target to $320 on, Monday, April 17th, 2023
- Christopher Raymond of "Piper Sandler" Upgraded from Hold to Buy and Increased Target to $346 on, Monday, April 17th, 2023
- Matthew Korn of "Morgan Stanley" Maintained at Buy with Decreased Target to $349 on, Wednesday, April 12th, 2023
- Phil Nadeau of "Cowen & Co." Maintained at Buy with Increased Target to $315 on, Thursday, February 16th, 2023
- Colin Bristow of "UBS" Maintained at Strong Buy with Increased Target to $340 on, Thursday, February 16th, 2023
Contributing Sources